Skip to main content

Blog

Edgewise Therapeutics Announces Positive Topline Results from CANYON Phase 2 Trial of Sevasemten in Individuals with Becker

...

Advance the Research Evolution: Introducing PPMD’s Dystrophinopathy Clinical Research Network

...

Catch up on PPMD Together: Virtual Edition – A Gathering of Families for Connection, Support, and Growth

...

This Year, I Am Grateful For Our Journey Together

...

Equitable Access in Clinical Trials—A Call for Action and Collaboration

...

WATCH: RGX-202 – AFFINITY DUCHENNE Pivotal Program and Functional Data (Webinar Recording)

...

PPMD Culminates 30th Anniversary with Celebratory “Investing in Every Future” Event

...

REGENXBIO Initiates Pivotal Phase of AFFINITY DUCHENNE® Trial of RGX-202 Gene Therapy, Reports Positive Functional Data

...

REGENXBIO Initiates Pivotal Phase of AFFINITY DUCHENNE® Trial of RGX-202 Gene Therapy, Reports Positive Functional Data

...

Calling All Adults with Duchenne & Becker: Join the 2025 PPMD Adult Advisory Committee

...